Does HFpEF represent a risk factor and a marker of cardiotoxicity in patients undergoing cancer treatment?

Back

ESC Premium Access

Does HFpEF represent a risk factor and a marker of cardiotoxicity in patients undergoing cancer treatment?

Session: Cardiotoxicity and development of heart failure

Topic: Cardio-Oncology

Speaker: Doctor B. von Kemp (Brussels, BE)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Berlinde von Kemp

University Hospital (UZ) Brussels, Brussels (Belgium)

1 presentation

0 follower

7 more presentations in this session

Heart rate variability-based prediction of early cardiotoxicity in breast-cancer patients treated with anthracyclines and trastuzumab

Speaker: Doctor N. Espinola-Zavaleta (Mexico City, MX)

Low clinical utility of global longitudinal strain in a real-world breast cancer population

Speaker: Doctor L. Ruane (Brisbane, AU)

Angiotensin receptor-neprilysin inhibitor (Sacubitril/Valsartan) in cancer therapy-related cardiac dysfunction: real-world experience from a nurse-led cardio-oncology clinic

Speaker: Miss P. Reehal (London, GB)

Clinical characteristics, resource use, and diagnostic accuracy of natriuretic peptides in cancer patients presenting with acute dyspnea to the Emergency Department

Speaker: Doctor P. Lopez Ayala (Basel, CH)

miRNAs profile as a signature for cardiovascular disease in long-term breast cancer female survivors: a pilot study

Speaker: Doctor A. Greatti (Ferrara, IT)

Access the full session

Cardiotoxicity and development of heart failure

Speakers: Doctor B. von Kemp, Doctor N. Espinola-Zavaleta, Doctor L. Ruane, Miss P. Reehal, Doctor P. Lopez Ayala...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources